quinine topical nasal spray (GLS-1200) / GeneOne, University of Pennsylvania - LARVOL DELTA

GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) (clinicaltrials.gov) - P2 | N=184 | Terminated | Sponsor: GeneOne Life Science, Inc. | Active, not recruiting ➔ Terminated; No longer enrolling

Trial termination • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) (clinicaltrials.gov) - P2 | N=184 | Active, not recruiting | Sponsor: GeneOne Life Science, Inc. | Terminated ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) (clinicaltrials.gov) - P2 | N=184 | Terminated | Sponsor: GeneOne Life Science, Inc. | Recruiting ➔ Terminated; No longer enrolling

Trial termination • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

GLS-1200 Topical Nasal Spray to Prevent Sinusitis After Endoscopic Sinus Surgery (clinicaltrials.gov) - P2 | N=99 | Not yet recruiting | Sponsor: GeneOne Life Science, Inc. | Trial completion date: Sep 2023 ➔ Sep 2024 | Trial primary completion date: Feb 2023 ➔ Dec 2023

Surgery • Trial completion date • Trial primary completion date • Otorhinolaryngology • Respiratory Diseases • Sinusitis

GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) (clinicaltrials.gov) - P2 | N=225 | Recruiting | Sponsor: GeneOne Life Science, Inc. | Trial primary completion date: Apr 2022 ➔ Dec 2022

Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

GLS-1200 Topical Nasal Spray to Prevent Sinusitis After Endoscopic Sinus Surgery (clinicaltrials.gov) - P2; N=99; Not yet recruiting; Sponsor: GeneOne Life Science, Inc.; Trial completion date: Sep 2022 ➔ Sep 2023; Trial primary completion date: Sep 2021 ➔ Feb 2023

Clinical • Trial completion date • Trial primary completion date • Otorhinolaryngology • Respiratory Diseases • Sinusitis

GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) (clinicaltrials.gov) - P2; N=225; Recruiting; Sponsor: GeneOne Life Science, Inc.; Trial completion date: Dec 2021 ➔ Dec 2022; Trial primary completion date: Sep 2021 ➔ Apr 2022

Clinical • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) (clinicaltrials.gov) - P2; N=225; Recruiting; Sponsor: GeneOne Life Science, Inc.; Trial completion date: Sep 2021 ➔ Dec 2021

Clinical • Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) in Health Care Personnel (clinicaltrials.gov) - P2; N=225; Recruiting; Sponsor: GeneOne Life Science, Inc.; Trial completion date: Mar 2021 ➔ Sep 2021; Trial primary completion date: Feb 2021 ➔ Aug 2021

Clinical • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) in Health Care Personnel (clinicaltrials.gov) - P2; N=225; Recruiting; Sponsor: GeneOne Life Science, Inc.; Trial completion date: Nov 2020 ➔ Mar 2021; Trial primary completion date: Sep 2020 ➔ Feb 2021

Clinical • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating patients with suspected or confirmed COVID-19 infection. (PubMed, Cochrane Database Syst Rev) - "The interventions included in these trials are povidone iodine, nitric oxide and GLS-1200 oral spray (the constituent of this spray is unclear and may not be antimicrobial in nature)...If a positive treatment effect is demonstrated when studies are available for inclusion in this review, it may not be large. In these circumstances in particular, where those receiving the intervention are otherwise fit and well, it may be a challenge to weigh up the benefits against the harms if the latter are of uncertain frequency and severity."

Clinical • Journal • Review • Allergy • Immunology • Infectious Disease • Novel Coronavirus Disease

GLS-1200Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) in Health Care Personnel (clinicaltrials.gov) - P2; N=225; Recruiting; Sponsor: GeneOne Life Science, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease

GLS-1200Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) in Health Care Personnel (clinicaltrials.gov) - P2; N=225; Not yet recruiting; Sponsor: GeneOne Life Science, Inc.

Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease

GeneOne Life Science announces US FDA approval of a phase 2 study of GLS-1200 nasal spray for Covid-19 prevention (PRWeb) - "GeneOne Life Science, Inc. announces today an Investigational New Drug (IND) approval by the U.S. Food and Drug Administration of a Phase 2 study of GLS-1200, its nasal spray for the prevention of COVID-19 infection. This study will recruit hospital personnel and other frontline healthcare workers who are at significantly higher risk for infection with COVID-19. In this study, GLS-1200 will be topically self-administered as a spray to the nose, the primary entry point for COVID-19 infection....This study of GLS-1200 will enroll a total of 225 participants into a randomized, double-blind, placebo-controlled clinical trial. The study will investigate whether three-times daily nasal administration of GLS-1200 over 4 weeks can prevent infection with COVID-19 while in use."

Clinical protocol • IND • New P2 trial • Infectious Disease • Novel Coronavirus Disease